Black Diamond Therapeutics reports FY2021 net loss $125.6M; cash $209.8M, runway into 2024

Black Diamond Therapeutics, Inc.

Net loss FY2021 $125.6M vs $67.3M YoY; Q4 loss $25.9M vs $22.6M.
Cash $209.8M at Dec 31, 2021 (down from $315.1M); sufficient to fund operations into 2024.
R&D spend $96.8M in 2021 (vs $48.2M); G&A $30.0M (vs $21.4M).
FDA allowed IND for BDTX-1535; Phase 1 study initiated for GBM and NSCLC with CNS metastases.
Appointed Elizabeth Montgomery as Chief People Officer, bringing nearly 20 years HR experience in life sciences.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.